Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients

Clinical and Vaccine Immunology

Volumn 18, Issue 7, 2011, Pages 1077-1082

  Herman, S ^a   Zurgil, N ^a   Machlav, S ^a   Shinberg, A ^a   Langevitz, P ^b   Ehrenfeld, M ^b   Deutsch, M ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 2; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MONOTHERAPY; PATHOGENESIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; TH1 TH2 BALANCE;

ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HOMEOSTASIS; HUMANS; METHOTREXATE; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960147677     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00061-11     Document Type: Article

References (31)

1. Alvarez-Lara, M. A., et al. 2004. The imbalance in the ratio of Th1 and Th2 helper lymphocytes in uraemia is mediated by an increased apoptosis of Th1 subset. Nephrol. Dial. Transplant. 19:3084-3090.
2. Arnett, F. C., et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324. (Pubitemid 18091653)
3. Bang, L. M., and G. M. Keating. 2004. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 18:1221-1239.
4. Cañete, J. D., et al. 2000. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann. Rheum. Dis. 59:263-268.
5. Chen, D. Y., J. L. Lan, F. J. Lin, and T. Y. Hsieh. 2004. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J. Rheumatol. 31:2189-2198.
6. Cronstein, B. N. 2005. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57:163-172.
7. Ebert, E. C. 2009. Infliximab and TNF alpha system. Am. J. Physiol. Gastrointest. Liver Physiol. 296:G612-G620.
8. Fairbanks, L. D., et al. 1999. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis. Biochem. J. 342:143-152. (Pubitemid 29410860)
9. Firestein, G. S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11(Suppl. 3):39-44.
10. Genestier, L., et al. 1998. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Investig. 102:322-328.
11. Herman, S., N. Zurgil, P. Langevitz, M. Ehrenfeld, and M. Deutsch. 2008. Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin. Exp. Rheumatol. 26:317-323.
12. Herman, S., N. Zurgil, P. Langevitz, M. Ehrenfeld, and M. Deutsch. 2004. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunol. Investig. 33:351-362.
13. Herman, S., N. Zurgil, P. Langevitz, M. Ehrenfeld, and M. Deutsch. 2003. The induction of apoptosis by methotrexate in activated lymphocytes as indicated by fluorescence hyperpolarization: a possible model for predicting methotrexate therapy for rheumatoid arthritis patients. Cell Struct. Funct. 28:113-122.
14. Hildner, K., et al. 1999. Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118:137-146.
15. Klareskog, L., et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681. (Pubitemid 38296553)
16. Klinkhoff, A. 2004. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 64:1267-1283. (Pubitemid 38916341)
17. Kremer, J. M. 2005. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J. Clin. Rheumatol. 11(Suppl. 3):55-62.
18. Kunkel, E. J. 2002. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160: 347-355.
19. Lee, B., J. Ratajczak, R. W. Doms, A. M. Gewirtz, and M. Z. Ratajczak. 1999. Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for HIV-1 infection. Blood 93:1145-1156.
20. Lee, Y. H., et al. 2008. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol. Int. 28:553-559.
21. Linsen, L., et al. 2005. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res. Ther. 7:R493-R502.
22. Lipsky, P. E., et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343:1594-1602.
23. Maini, R. N., and P. C. Taylor. 2000. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51:207-229.
24. Prevoo, M. L. L., et al. 1995. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44-48.
25. Shen, C., et al. 2005. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21:251-258.
26. Tak, P. P. 2005. Effects of infliximab treatment on rheumatoid synovial tissue. J. Rheumatol. Suppl. 74:31-34.
27. Tanaka, Y. 2008. Paradigm shift in the treatment of rheumatoid arthritis by biologics. Rinsho Byori 56:309-315.
28. VanderBorght, A., P. Geusens, J. Raus, and P. Stinissen. 2001. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin. Arthritis Rheum. 31:160-175.
29. Weaver, A. L. 2004. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43(Suppl. 3):17-23.
30. Weyand, C. M., E. Bryl, and J. J. Goronzy. 2000. The role of T cells in rheumatoid arthritis. Arch. Immunol. Ther. Exp. 48:429-435.
31. + T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus. Clin. Exp. Immunol. 138:342-347.